Martin Görner

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler et al. · Journal of Clinical Oncology · 2014 · 484 citations

Medicine, Oncology, Pharmacology +13

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 400 citations · Full text

Medicine, Hematology, Oncology +6

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Lisa Leypoldt, Diana Tichy, Britta Besemer et al. · Journal of Clinical Oncology · 2023 · 141 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Gemma 2: Improving Open Language Models at a Practical Size

Gemma Team, Morgane Rivière, Shreya Pathak et al. · arXiv (Cornell University) · 2024 · 134 citations · Full text

Computing, Computer Science, Computational Linguistics +13

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

Uwe Pelzer, Krystian Kubica, Jens Stieler et al. · Journal of Clinical Oncology · 2008 · 126 citations

Medicine, Oncology, Pharmacology +12